- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02007239
Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
Cytokine Blockade With Tocilizumab in Patients With Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects with hemophagocytic lymphohistiocytosis (HLH) often have life-threatening complications at the time of diagnosis resulting from excessive inflammation. This excessive inflammation is driven by abnormally high levels of cytokines--proteins involved in inflammation. Standard therapy for HLH does not directly target these cytokines. Tocilizumab is a medicine that blocks one of the cytokines that is elevated in patients with HLH.
This is an open-label single-arm uncontrolled trial with biologic endpoint. This study will use tocilizumab in subjects with HLH and high cytokine levels in an attempt to decrease the damage caused by these proteins. All subjects will receive standard therapy, in addition to tocilizumab. We hypothesize the tocilizumab will decrease levels of certain important cytokines. This may make it easier to treat subjects with HLH overall.
TCZ will be administered as a single dose (8mg/kg) intravenously. Eligible subjects will be inpatients at the Children's Hospital of Philadelphia (CHOP) main campus. 10 subjects with HLH will be enrolled. All subjects will be initiated on standard HLH-directed treatment. Cytokine levels [including serum interferon (IFN-γ) and interleukin (IL-6)] will be monitored, in addition to other laboratory and clinical markers of HLH disease activity.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females age 3 months to 25 years.
- Fulfill the clinical diagnostic criteria for HLH, as defined by the Histiocyte Society (see Table 1). Only patients with de novo HLH are eligible.
Evidence of cytokine release syndrome (CRS), as defined by EITHER:
i. Known elevated interferon-γ and interleukin-6 ≥2x ULN, OR ii. If cytokine levels are unknown at the time of study enrollment:
a. Fever of at least 38.5º celsius at minimum of once every 24 hours for at least 48 hours, AND either i. Respiratory insufficiency requiring oxygen supplementation of at least 2 Liter by nasal cannula for at least 12 hours (also including invasive, noninvasive, continuous positive airway pressure or biphasic airway pressure for the purpose of treating respiratory failure), OR ii. Vasoactive infusion for at least 12 hours, including dopamine ≥5mcg/kg/min, dobutamine≥5mcg/kg/min, or any dose of epinephrine, norepinephrine, milrinone, or vasopressin.
- Patients must be planned to initiate HLH-directed therapy within 24 hours of study enrollment.
- Girls >= 11 years of age must have a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.
- Parental/guardian permission (informed consent)
Exclusion Criteria:
- On-going or planned participation in another clinical trial involving HLH-directed treatment
- Previous administration of any other biologic agent targeted at cytokine blockade within 5 days of enrollment.
- Renal insufficiency defined by estimated glomerular filtration rate (based on modified Schwartz formula) <50 ml/min, or need for renal replacement therapy.
- Hepatic dysfunction as defined by serum alanine aminotransferase (ALT)>=10x upper limit of normal (ULN). For the purposes of this study, the ULN for ALT is 45 U/L.
- HLH that is relapsed, refractory, or considered to be therapy-related, as in the case of T cell-activating therapies.
- Established prior diagnosis of underlying rheumatologic condition, including juvenile idiopathic arthritis.
- Pregnant or lactating females.
- Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
- Suspected gastrointestinal perforation.
- Known or suspected demyelinating central nervous system disease.
- Known history of tuberculosis.
- Transfusion-refractory thrombocytopenia defined as inability to maintain platelet count over 30,000/ul for at least 6 hours with transfusion support.
- Known active herpetic infection.
- Inability to start HLH-directed immunochemotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment
single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
|
single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in serum interferon-gamma levels after tocilizumab (TCZ) administration
Time Frame: baseline, 24 -36 hours, and 4-7 days after administration of TCZ
|
Assess change in interferon gamma levels from the screening visit to the measurements taken within 24-36 hours and at 4-7 days after drug administration.
|
baseline, 24 -36 hours, and 4-7 days after administration of TCZ
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in other cytokine levels (interleukin-6, interleukin-10, tumor necrosis factor-alpha, etc.)
Time Frame: baseline, 24-36 hour, then weekly for 4 weeks after administration of TCZ
|
Cytokine levels [IL-1, IL-2, sIL-2r, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, Tumor necrosis factor-alpha (TNF-α) and IFN-γ] will be assessed at baseline, within 24-36 hours, then weekly for 4 weeks after TCZ administration;
|
baseline, 24-36 hour, then weekly for 4 weeks after administration of TCZ
|
Presence of HLH disease activity for each subject following TCZ administration
Time Frame: within 1 week of administration of TCZ
|
HLH disease activity markers will be assessed for each subject (fever, ferritin, cardiopulmonary support requirements, cytopenias, coagulation tests, etc.)
|
within 1 week of administration of TCZ
|
Degree of hepatic function, cytopenias and infection in subjects following administration of TCZ
Time Frame: up to 1 year of administration of TCZ
|
Degree of hepatic function, presence (or absence) of cytopenia/infection will be assessed based on changes in laboratory and clinical markers following administration of TCZ.
|
up to 1 year of administration of TCZ
|
Overall survival of subjects
Time Frame: day 100 and survival to completion of therapy (blood/marrow transplant, if applicable)
|
Overall survival of subjects will include survival to day 100, and survival to completion of therapy (HSCT for primary HLH, and end of induction therapy for secondary HLH).
|
day 100 and survival to completion of therapy (blood/marrow transplant, if applicable)
|
Collaborators and Investigators
Investigators
- Principal Investigator: David Teachey, MD, Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia
Publications and helpful links
General Publications
- Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002 Oct 1;100(7):2367-73. doi: 10.1182/blood-2002-01-0172.
- Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, Pan B, Zhao F, Liao C, Luo C. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol. 2008 Oct;143(1):84-91. doi: 10.1111/j.1365-2141.2008.07298.x. Epub 2008 Jul 31.
- Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012 Apr;34(4):788-802.e3. doi: 10.1016/j.clinthera.2012.02.014. Epub 2012 Mar 22.
- Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013 Jun 27;121(26):5154-7. doi: 10.1182/blood-2013-02-485623. Epub 2013 May 15.
- Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25. Erratum In: N Engl J Med. 2016 Mar 10;374(10):998.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-010459
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophagocytic Lymphohistiocytosis
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Children's Hospital Medical Center, CincinnatiBaylor College of Medicine; Sobi, Inc.RecruitingHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumLight Chain Bioscience - Novimmune SATerminatedHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumHarvard Medical School (HMS and HSDM); Brigham and Women's HospitalCompletedHemophagocytic LymphohistiocytosesUnited States
-
University of California, San FranciscoIncyte CorporationNot yet recruitingRuxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Hemophagocytic LymphohistiocytosesUnited States
-
Beijing Friendship HospitalNot yet recruitingEBV | Hemophagocytic Lymphohistiocytoses | MetabonomicsChina
-
Beijing Friendship HospitalRecruitingHemophagocytic LymphohistiocytosisChina
-
St. Jude Children's Research HospitalIncyte Corporation; North American Consortium for Histiocytosis; Cures Within...RecruitingHemophagocytic LymphohistiocytosisUnited States
-
Swedish Orphan BiovitrumSeventh Framework ProgrammeCompletedHemophagocytic LymphohistiocytosisUnited States, France, Italy, Spain, United Kingdom
Clinical Trials on tocilizumab
-
University of ChicagoActive, not recruiting
-
CelltrionNot yet recruiting
-
University of ChicagoRecruiting
-
Reade Rheumatology Research InstituteZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingRheumatoid ArthritisNetherlands
-
Memorial Sloan Kettering Cancer CenterTerminatedCOVID-19United States
-
University of ChicagoCompleted
-
Karadeniz Technical UniversityCompletedCOVID-19 | Mortality | Critical Care | TocilizumabTurkey
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Università Politecnica delle MarcheAzienda Ospedaliera Ospedali Riuniti Marche NordUnknown
-
Hospital of PratoUnknown